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Abstract
To eliminate hepatitis C virus (HCV) from infected hepatocytes, we generated two therapeutic molecules specifically
activated in cells infected with HCV. A dominant active mutant of interferon (IFN) regulatory factor 7 (IRF7) and a negative
regulator of HCV replication, VAP-C (Vesicle-associated membrane protein-associated protein subtype C), were fused with
the C-terminal region of IPS-1 (IFNb promoter stimulator-1), which includes an HCV protease cleavage site that was modified
to be localized on the ER membrane, and designated cIRF7 and cVAP-C, respectively. In cells expressing the HCV protease,
cIRF7 was cleaved and the processed fragment was migrated into the nucleus, where it activated various IFN promoters,
including promoters of IFNa6, IFNb, and IFN stimulated response element. Activation of the IFN promoters and suppression
of viral RNA replication were observed in the HCV replicon cells and in cells infected with the JFH1 strain of HCV (HCVcc) by
expression of cIRF7. Suppression of viral RNA replication was observed even in the IFN-resistant replicon cells by the
expression of cIRF7. Expression of the cVAP-C also resulted in suppression of HCV replication in both the replicon and HCVcc
infected cells. These results suggest that delivery of the therapeutic molecules into the liver of hepatitis C patients, followed
by selective activation of the molecules in HCV-infected hepatocytes, is a feasible method for eliminating HCV.
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Introduction
Hepatitis C virus (HCV) is a major cause of chronic liver
diseases. A high risk of chronicity is the major concern of HCV
infection, since chronic HCV infection often leads to liver cirrhosis
and hepatocellular carcinoma [1,2]. Although the proportion of
patients achieving a sustained virological response (SVR) has been
increased by the recent used of combination therapy with
pegylated-interferon-a (PEG-IFNa) and ribavirin (RBV), half of
patients still exhibit no response to this therapy, suggesting that the
IFN signaling pathway is modulated by HCV infection. In
addition, various side effects have been reported in more than 20%
of patients treated with this combination therapy [3].
HCV belongs to the family Flaviviridae and possesses a single
positive-stranded RNA genome that encodes a single polyprotein
composed of about 3,000 amino acids. The HCV polyprotein is
processed into 10 viral proteins by host and viral proteases. Viral
structural proteins, including the capsid protein and two envelope
proteins, are located in the N-terminal one third of the polypro-
tein, followed by nonstructural proteins. The NS2 protease cleaves
its own carboxyl terminus and NS3 cleaves the downstream
positions to produce NS4A, NS4B, NS5A and NS5B. Although
laboratory strains of HCV propagating in cell culture (HCVcc)
have been established based on the full-length genome of the
genotype 2a JFH1 strain [4], establishment of a robust cell culture
system capable of propagating serum-derived HCV from hepatitis
C patients has not yet been achieved.
Type I IFN exhibits potent antiviral effects through the
regulation of hundreds of IFN-stimulated genes (ISGs) which
encode proteins involved in the establishment of antiviral state in
cells [5]. IFNs induce transcription of ISGs through activation of
the Jak-STAT pathway [6]. Binding of type I IFN to the IFN
receptor induces phosphorylation of the receptor-associated
tyrosine kinases, Jak1 and Tyk2, and then these kinases activate
STAT1 and STAT2. The phosphorylated STATs migrate into the
nucleus and activate ISG promoters through binding to the
specific responsible elements. HCV infection has been suggested to
impair the IFN production through multiple pathways. The IFN-
induced Jak-STAT signaling is inhibited in cells and transgenic
mice expressing HCV proteins and in the liver biopsy samples of
chronic hepatitis C patients [7–9].
Induction of type I IFN upon infection with pathogens is crucial
for innate immunity, and it is mediated by the activation of
pattern-recognition receptors, including Toll-like receptors (TLRs)
and cytosolic receptors, such as RIG-I and MDA5 [10–12]. The
induction of type I IFN is primarily controlled at the gene
transcriptional level, wherein a family of transcription factors
known as IFN regulatory factors (IRFs) play a pivotal role. IRF3
PLoS ONE | www.plosone.org 1 January 2011 | Volume 6 | Issue 1 | e15967and IRF7 are known to be essential for the RIG-I-, MDA5-, and
TLR-mediated type I IFN production pathways. IRF3 is induced
primarily by a response to initiate IFNb production, whereas IRF7
is induced by IFNb and participates in the late phase for IFNb
induction [13]. All TLRs, except for TLR3, activate the MyD88-
dependent pathway, whereas TLR3 and TLR4 activate the TRIF-
dependent pathway. HCV NS3/4A protease has been shown to
impair the production of IFNb as well as the subsequent IFN-
inducible genes through the inactivation of the adaptor molecules
involved in the TLR-dependent and -independent signaling
pathways [14–18]. On the other hand, Vilasco et al. suggested
that impairment of IKKi - which, along with TBK1, is one of the
important factors participating in IRF3 phosphorylation and
activation - in the HCV replicon cells plays at least a partial role in
the restoration of type I IFN signaling pathways [19]. In addition,
IRF7 was shown to participate in the positive feedback of type I
IFN signaling through the IFN receptor [13]. Therefore, we tried
to examine the effect of exogenous expression of IRF7 under the
assumption that IRF7 is a potent type I IFN inducer and capable
of modulating the viral propagation in hepatocytes infected with
HCV.
In this study, we generated two therapeutic molecules consisting
of a dominant active mutant of IRF7 or VAP-C, a negative
regulator of HCV replication [20], followed by the C-terminal
region of IFN promoter stimulator 1 (IPS-1), including the
cleavage site of the HCV NS3/4A protease, which was modified
so that the cleavage site localized on the ER membrane [21]. The
expression of the plasmids encoding these molecules in the HCV
replicon and HCVcc-infected cells resulted in a substantial
suppression of HCV propagation, suggesting the possibility that
these or other similar molecules could be used therapeutically to
eliminate HCV from hepatocytes infected with HCV.
Results
IRF7m, a dominant active mutant of IRF7, activates the
IFN promoters in cells replicating HCV
Previous studies have shown that an IRF7 mutant, IRF7m,
lacking the amino acid residues from 284 to 454, a region that
includes the auto-inhibitory domain (from amino acid residue 305
to 467), and an IRF3 mutant, IRF3m, carrying the substitution of
Ser
396 to Asp in the carboxyl terminal region (Fig. 1A), induced a
potent activation of type I IFN promoter in non-hepatic cell lines
irrespective of viral infection [22–25]. We first examined the effect
of the expression of the IRF dominant active mutants on the
inhibition of HCV RNA replication through the production of
type I IFN. HCV replicon cells and Huh7OK1 cells infected with
HCVcc were transfected with the plasmids encoding either wild-
type or dominant active mutant of IRF3 or IRF7 together with the
reporter plasmids encoding a luciferase gene under the control of
the promoters of IFNa6, IFNb and ISRE, respectively. Among
these examined constructs, we observed significant activation of
the promoters of IFNa6 and ISRE in the replicon and HCVcc-
infected cells compared with naı ¨ve and mock-infected cells upon
expression of IRF7m, while we observed no activation of the
IFNa6 promoter in cells expressing IRF3m (Figs. 1 B and 1C).
Potent stimulation of the IFNb promoter was observed in the
replicon cells expressing IRF7m but not in cells infected with
HCVcc. Next we examined the antiviral activity of the IRF
constructs in both replicon (Fig. 1D) and HCVcc-infected cells
(Fig. 1E). The expression of the plasmid encoding IRF7m resulted
in potent suppression of viral protein and viral RNA syntheses in
both cell types. Although expression of IRF3m induced a slight
suppression of viral propagation in cells infected with HCVcc,
expression of the IRF constructs except for IRF7m did not induce
the significant suppression of viral replication and propagation.
These results suggest the possibility of elimination of HCV
through a specific induction of type I IFN by the expression of
IRF7m in HCV-infected cells.
cIRF7, a chimeric construct of IRF7m, specifically activates
the IFN promoters in cells replicating HCV
To induce IFNs in cells infected with HCV but not in
uninfected cells through a selective activation of IRF7m, we
constructed a chimeric IRF7 (cIRF7) consisting of the IRF7m
fused with FLAG-tag and the C-terminal amino acid residues from
503 to 540 of IPS-1 modified to be localized on ER (Fig. 2A upper)
[21]. HCV NS3/4A protease cleaves the carboxyl site of Cys
508 in
the C-terminal domain of IPS-1. Although cIRF7 is anchored in
the ER and exhibits no activation in uninfected cells, cIRF7 would
be cleaved by the NS3/4A protease in cells infected with HCV
and the released N-terminal fragment would migrate into the
nucleus and activate various IFN promoters (Fig. 3). Immunoblot
analyses revealed that cIRF7 was cleaved in 293T cells expressing
HCV NS3/4A protease of a wild type but not in those expressing
the mutant protease NS3/4A(S139A), and a mutant cIR-
F7(C508A) which has a substitution of Cys
508 to Ala, exhibited
resistance to the cleavage by the HCV protease (Fig. 2A bottom).
To assess a specific activation of the IFN promoters after cleavage
of the cIRF7 by HCV NS3/4A, 293T cells expressing FLAG-
tagged HCV proteases were transfected with the plasmids
encoding the luciferase gene under the control of the promoter
of IFNa6, IFNb or ISRE together with the plasmid encoding
either cIRF7 or cIRF7(C508A). Expression of cIRF7 but not of
cIRF7(C508A) induced the activation of the IFNa6, IFNb and
ISRE promoters in cells expressing HCV NS3/4A protease but
not in those expressing the mutant protease NS3/4A(S139A)
(Fig. 2B). Next we examined the activation of the IFN promoters
associated with the expression of the plasmid encoding cIRF7 in
the replicon and HCVcc-infected cells. Expression of cIRF7 but
not of cIRF7(C508A) induced the activation of the IFN promoters
in both cell types (Figs. 2C and 2D). On the other hand, these
promoters were not activated by the expression of cIRF7 in the
replicon cells harboring subgenomic RNA of Japanese encephalitis
virus (JEV) and Huh7 cells infected with JEV (Fig. 2E). These
results suggest that the cIRF7 expression is a feasible method for
specifically activating the IFN promoters in cells infected with
HCV.
Specificity of activation of the IFN promoters by the
expression of cIRF7
To further examine the specificity of the activation of the IFN
promoters by the expression of cIRF7 in cells replicating HCV, a
plasmid encoding either cIRF7 or IRF7m was co-transfected with
that encoding the luciferase gene under the ISRE promoter into
the HCV replicon or HCVcc-infected cells and cultured in the
presence or absence of inhibitors for HCV replication. Treatment
with an HCV protease inhibitor (BILN2061) or cyclosporine A
(CsA) inhibited the activation of the ISRE promoter by the
expression of cIRF7 in the HCV replicon and HCVcc-infected
cells in a dose-dependent manner, in contrast to the resistance to
the treatments in cells expressing the IRF7m (Fig. 4A and Fig. 4B).
Recently, it was shown that an NS3/4A protease of GB virus B
(GBV-B), which is the virus genetically related most closely to
HCV, also impairs the dsRNA-induced IFN production through a
cleavage of IPS-1[26]. Therefore, to assess the possibility of
activation of cIRF7 by other flaviviral proteases, cleavage of cIRF7
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PLoS ONE | www.plosone.org 2 January 2011 | Volume 6 | Issue 1 | e15967Figure 1. Dominant active mutant of IRF7 activates IFN promoters in cells replicating HCV. (A) Structures of IRF3, IRF7 and the dominant
active mutants, IRF3m and IRF7m. The DNA-binding domain, nuclear export sequence, transactivation domain, association domain, inhibitory
domain, and signal response domain are indicated as DBD, NES, TAD, AD, ID, and SRD, respectively. Huh7 cells and HCV replicon cells (1610
5 cells/
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expressing the viral proteases of HCV, GBV and JEV.
Immunoblot analyses revealed that cIRF7 was processed by the
viral proteases of HCV and GBV but not by that of JEV and the
activation of the IFN promoters was well correlated with the
cleavability of the cIRF7 (Fig. 4C). Although the GBV protease
exhibited an efficient activation of cIRF7 comparable to HCV
protease, processing of cIRF7 and activation of the IFN promoters
by the GBV protease was not inhibited by the pretreatment with
the HCV protease inhibitor (Figs. 4D and 4E). These results
indicate that cIRF7 is capable of activating the IFN promoters
through a specific cleavage by the protease in cells infected with
HCV.
Nuclear localization of cIRF7 in cells expressing HCV
protease
From these results, it was suggested that cIRF7 is cleaved by the
HCV protease and the processed fragment migrates into the
nucleus and activates IFN promoters (Fig. 3). To confirm the
nuclear localization of the cleaved cIRF7, we constructed an
EGFP-cIRF7 and determined its subcellular localization in cells
expressing the HCV protease and in the HCV replicon cells by
confocal microscopy. Nuclear accumulation of the cIRF7 was
observed in cells expressing EGFP-cIRF7 together with NS3/4A,
but not in those with NS3/4A(S139A) or NS5A and also not in
cells co-expressing EGFP-cIRF7(C508A) and NS3/4A (Fig. 5A).
Furthermore, expression of EGFP-cIRF7 but not of EGFP-
cIRF7(C508A) induced a nuclear accumulation of cIRF7 in the
HCV replicon cells, and nuclear localization of the cIRF7
abrogated the expression of viral antigen (NS3), in contrast to
the co-localization of EGFP-cIRF7(C508A) and the ER marker
PDI, which had no discernible antiviral effect (Fig. 5B). These
results suggest that cIRF7 is capable of suppressing HCV
replication through an HCV protease-dependent cleavage,
migration into the nucleus and activation of the IFN promoters.
Suppression of HCV replication by the expression of
cIRF7
To examine the inhibitory effect of the expression of cIRF7 on
HCV replication, a plasmid encoding either cIRF7 or cIR-
F7(C508A) was transfected into the HCV replicon and HCVcc-
infected cells, and HCV replication was evaluated by immuno-
blotting and real-time PCR. The expression of cIRF7 but not of
cIRF7(C508A) resulted in cleavage by the HCV protease, and a
clear reduction of viral protein and RNA syntheses in both
replicon and HCVcc-infected cells (Figs. 6A and 6B). In addition,
we examined the effect of cIRF7 on the replication of HCV in the
4bR replicon cells [27,28], which have been shown to exhibit
more resistant to the IFNa treatment than Con1 replicon cells
(Fig. 6C upper left). Expression of the cIRF7 in the 4bR replicon
cells but not in those cured HCV RNA (4bRc cells) induced an
activation of the ISRE promoter (Fig. 6C lower left). Expression of
cIRF7 but not of cIRF7(C508A) also resulted in processing by the
HCV protease and suppression of viral protein and RNA
syntheses in the 4bR replicon cells (Fig. 6C right panels).
Suppression of HCV replication by the expression of
cVAP-C
Human vesicle-associated membrane protein-associated protein
subtype A (VAP-A) and B (VAP-B) are known to be involved in the
regulation of membrane trafficking, lipid transport and metabo-
lism, and the unfolded protein response [29]. VAP-A and VAP-B
have been shown to be involved in the replication of HCV, and we
have shown recently that human VAP-C, a splicing variant of
VAP-B, negatively regulates HCV replication by interfering with
the interaction of VAP-A and VAP-B with HCV NS5B [20]. We
next examined the possibility of using a selective activation of
VAP-C to suppress HCV replication in cells infected with HCVcc.
We generated expression plasmids encoding a chimeric VAP-C
fused with the IPS-1 sequence (cVAP-C), a cVAP-C(C508A)
which is made resistant to the HCV protease by a substitution in
the cleavage site similar to the substitutions made in cIR-
F7(C508A), or VAP-C (Fig. 7A). The cVAP-C was cleaved in
cells infected with HCVcc, and expression of cVAP-C and VAP-C
suppressed expression of NS5A, in contrast to the weak reduction
of NS5A in the infected cells expressing cVAP-C(C508A),
probably due to a slight cleavage of cVAP-C(C508A) (Fig. 7B,
top). Furthermore, the production of viral RNA and infectious
particles in the culture supernatants of cells infected with HCVcc
was also impaired by the expression of cVAP-C and VAP-C, but
not of cVAP-C(C508A) in a dose-dependent manner (Fig. 7B,
middle and bottom). Collectively, these results suggest that delivery
of the therapeutic molecules into liver of hepatitis C patients,
followed by selective activation of the molecules in HCV-infected
hepatocytes, is a feasible method for eliminating HCV.
Discussion
An effective prophylactic vaccine against HCV has not been
developed yet. Although combination therapy consisting of PEG-
IFNa and RBV has been introduced for the treatment of hepatitis
C patients, and 50% of individuals infected with genotype 1
achieved a SVR, this treatment is sometimes associated with
serious side effects, including depression and anemia [3].
Therefore, new anti-HCV drugs targeted to HCV protease and
polymerase and capable of optimizing therapy are currently in the
early stages of the development [30,31]. However, it is difficult to
achieve a complete removal of viruses by antiviral drugs targeted
to the viral enzymes from patients persistently infected with RNA
viruses that exhibit a quasispecies nature, such as human
immunodeficiency virus (HIV) and HCV. Viral quasispecies are
not a simple collection of diverse mutants but a group of inter-
active variants capable of adapting to new environments [32].
Furthermore, introduction of antiviral drugs may induce an
emergence of drug-resistant breakthrough viruses as seen in the
case of HIV infection. Therefore, a novel therapeutic approach for
hepatitis C patients in addition to the current chemotherapies is
required to overcome serious adverse effects and improve the ratio
of patients achieving SVR.
In this study, we have generated two therapeutic molecules,
cIRF7 and cVAP-C, which are selectively activated in cells
well) (B), and Huh7OK1 cells (7.5610
4 cells/well) infected with HCVcc at an moi of 1 and incubated for 72 h (C) were transfected with 100 ng of
plasmid encoding the luciferase gene under the control of the IFNa6, IFNb, or ISRE promoter together with an empty vector (EV) or a plasmid
encoding each of the IRF constructs. The relative luciferase activity of cell lysates was determined at 24 h post-transfection. HCV replicon cells (3610
5
cells/well) (D) and Huh7OK1 cells (1.5610
5 cells/well) infected with HCVcc at an moi of 1 and incubated for 72 h (E) were transfected with EV or a
plasmid encoding each of the IRF constructs and the expressions of NS5A, IRFs, and GAPDH (upper panel) and synthesis of viral RNA (lower panel) at
72 h post-transfection were determined by immunoblotting and real-time PCR after standardization with GAPDH, respectively. The data shown in
this figure are representative of three independent experiments. The error bars represent the standard deviations. Asterisks indicate significant
differences (**P,0.01) versus the control cells or mock-infected cells.
doi:10.1371/journal.pone.0015967.g001
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PLoS ONE | www.plosone.org 4 January 2011 | Volume 6 | Issue 1 | e15967Figure 2. Construction of cIRF7 capable of activating the IFN promoters in cells replicating HCV. (A top) Schematic representation of the
cIRF7 constructs. cIRF7 consists of IRF7m, FLAG-tag, and IPS-1 (503 to 540 amino acid residues) sequences containing a cleavage site by HCV NS3/4A
protease, a transmembrane domain and a cytoplasmic region modified to localize on the ER. cIRF7(C508A) has a substitution of Cys508 to Ala which
renders it resistant to the cleavage by the HCV protease. (A bottom) Immunoblot analyses of 293T cells transfected with a plasmid encoding either
cIRF7 or cIRF7(C508A) together with either an empty vector (EV) or a plasmid encoding either FLAG-tagged HCVNS3/4A or FLAG-tagged HCVNS3/4A
(S139A). (B) 293T cells (2610
5 cells/well) were transfected with a plasmid of EV, FLAG-tagged HCVNS3/4A or FLAG-tagged HCVNS3/4A(S139A) in
combination with a plasmid of EV, cIRF7 or cIRF7 (C508A) together with 100 ng of the reporter plasmid encoding the luciferase gene under the
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HCV- infected cells, we employed the C-terminal amino acid
sequence of human IPS-1, which has been identified as an adaptor
molecule involved in the RIG-like receptor (RLR) signaling
pathways. It has been demonstrated that HCV NS3/4A protease
efficiently cleaves the upstream position of the transmembrane
region of IPS-1 on the mitochondrial outer membrane and
disrupts the IFN signaling pathway [15–18]. Furthermore, to
avoid induction of mitochondrial dysfunction and cell death due to
the expression of the therapeutic molecules on the mitochondria,
we replaced three arginine residues among the C-terminal five
residues of IPS-1 with non-charged amino acid glycine residues
(RRRLH to GGGLH) so that these three residues would be
localized on the ER membrane [21]. HCV is suggested to replicate
on the ER membrane, and therefore subcellular localization and
distance of the cleavage site of the substrates from the membrane
could be crucial for an efficient processing. The tightly regulated
activation of the therapeutic molecules in cells replicating HCV
observed in this study might be largely attributable to the ER
localization of the therapeutic molecules.
Irrespective of IFN sensitivity, the expression of cIRF7 in the
HCV replicon cells induced the activation of type I IFN promoter
and inhibited the viral RNA replication, suggesting the possibility
that cIRF7 could be used for the treatment of hepatitis C patients
who are infected with HCV resistant to IFNa therapy. The
expression of IRF3m in cells infected with HCVcc induced a
higher antiviral response than that in the Con1 replicon cells in
spite of the comparable transcription of IFNb mRNA between the
two cell types Fig. 1), suggesting that differences among HCV
genotypes might be caused to the difference to the sensitivity of
IFNb. To assess the real efficacy of cIRF7 for suppression of HCV
replication, we must await the establishment of robust cell culture
systems capable of propagating various genotypes of HCV derived
from the sera of hepatitis C patients.
It has been shown previously that HCV interferes with the
induction of type I IFN through the cleavage of IPS-1 by NS3/4A
protease [15–18], the interaction of NS5A with MyD88, a major
adaptor molecule of TLRs [33], and the intervention of the IFNa-
activated Jak-STAT signaling pathway by HCV proteins [7–9].
After cleavage by the HCV protease, the processed cIRF7
migrates into the nucleus and activates various IFN promoters,
and it may participate in regulation of the expression of hundreds
of ISGs, suggesting that cIRF7 is capable of inducing an antiviral
response through the Jak-STAT-independent pathway. Although
it has been reported previously that the basal expression of IRF7
and the IRF7-induced activation of the IFNa promoter are
impaired in the HCV replicon cells [34], in this study we have
shown that cIRF7 is activated in cells infected with HCVcc and
capable of inducing type I IFN. Collectively, these results suggest
that cIRF7 is capable of eliminating HCV that persistently infects
control of the IFNa6, IFNb or ISRE promoter, and luciferase activity was determined at 24 h post-transfection. (C) HCV replicon cells (1.5610
5 cells/
well) and (D) Huh7OK1 cells (7.5610
4 cells/well) infected with HCVcc at an moi of 1 and incubated for 72 h were transfected with 100 ng of each of
the reporter plasmids together with plasmid of EV, cIRF7 or cIRF7(C508A) and luciferase activity was determined at 24 h post-transfection. (E) Huh7
cells, HCV subgenomic replicon cells, and JEV subgenomic replicon cells (1610
5 cells/well) (top) and Huh7OK1 cells (7.5610
4 cells/well) infected with
JEV and HCV (bottom) at an moi of 0.008, 0.04, 0.2, and 1 and incubated for 24 h and 72 h, respectively, were transfected with 100 ng of each of the
reporter plasmids together with cIRF7 and the luciferase activity was determined at 24 h post-transfection. The data shown in this figure are
representative of three independent experiments. The error bars represent the standard deviations. Asterisks indicate significant differences
(*P,0.05, **P,0.01) versus the control cells or mock-infected cells.
doi:10.1371/journal.pone.0015967.g002
Figure 3. Scheme of activation of the therapeutic molecule in cells infected with HCV. The chimeric molecules are cleaved by HCV NS3/4A
protease and the released fragments inhibit propagation of HCV through induction of IFN after translocation into the nucleus (cIRF7) or disruption of
the replication complex (cVAP-C), whereas the molecule is stably anchored in the ER within uninfected cells.
doi:10.1371/journal.pone.0015967.g003
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PLoS ONE | www.plosone.org 6 January 2011 | Volume 6 | Issue 1 | e15967Figure 4. Specificity of activation of the IFN promoters by the expression of cIRF7. (A) HCV replicon cells (1.5610
5cells/well) or Huh7OK1 cells
(7.5610
4 cells/well) infected with HCVcc at an moi of 1 and incubated for 72 h were treated with various concentrations of HCV protease inhibitor (A) or
cyclosporine A (CsA) (B), transfected with an empty vector (EV) (white bars) or plasmids encoding cIRF7 (black bars) or IRF7m (gray bars) together with 100 ng
of a reporter plasmid encoding the luciferase gene under the control of the ISRE promoter, and luciferase activity was determined at 24 h post-transfection.
(C top) A plasmid encoding cIRF7 was co-transfected with a plasmid encoding either FLAG-tagged HCVNS3/4A, FLAG-tagged GBVNS3/4A, or HA-tagged
JEVNS2b/3 into 293T cells, and the expressions of cIRF7, viral proteases and GAPDH were determined by immunoblotting. (C bottom) 293T cells (2610
5 cells/
well) transfected with a plasmid encoding either EV (dark gray bars), FLAG-tagged HCVNS3/4A (black bars), FLAG-tagged GBVNS3/4A (white bars), or HA-
tagged JEVNS2b/3 (gray bars) together with 100 ng of the plasmid encoding the luciferase gene under the control of the promoter of either IFNa6, IFNb or
ISRE, and luciferase activity was determined at 24 h post-transfection. (D) 293T cells (2610
5 cells/well) were transfected with 100 ng of the reporter plasmids
together with plasmids encoding EV (gray bars), FLAG-tagged HCVNS3/4A (black bars) or FLAG-tagged GBVNS3/4A (white bars) in the presence or absence of
the HCV protease inhibitor, and luciferase activity was determined at 24 h post-transfection. (E) cIRF7 was co-expressed with FLAG-tagged HCVNS3/4Ao r
FLAG-tagged GBVNS3/4A in 293T cells in the presence or absence of the HCV protease inhibitor, and the expressions of cIRF7, viral proteases and GAPDH were
determined by immunoblotting. The data shown in this figure are representative of three independent experiments. The error bars represent the standard
deviations. Asterisks indicate significant differences (*P,0.05, **P,0.01) versus the control cells or mock-infected cells.
doi:10.1371/journal.pone.0015967.g004
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type I IFN.
It is well known that patients achieving a rapid viral clearance
by the treatment with PEG-IFNa showed a significant up-
regulation of ISG, whereas a high level expression of ISG is
observed in nonresponsive patients before IFN therapy, probably
due to a rapid induction of negative regulators for the IFN
signaling pathway, such as the suppressor of cytokine signaling
proteins [35,36]. These results suggest that chronic hepatitis C
patients with a pre-activated IFN signaling pathway respond
poorly to IFN therapy. In this study we also demonstrated that
activation of various IFN promoters by the expression of the
dominant active mutants of IRFs was more accentuated in cells
replicating HCV rather than naı ¨ve cells, probably due to an
undetectable expression of ISG in cells replicating HCV RNA as
described previously [37]. However, the precise mechanisms
underlying the enhancement of IFN activity by the expression of a
dominant active mutant of IRFs in cells replicating HCV remain
unknown. Fillipowicz et al. suggested the possibility of recovery of
the sensitivity to IFN therapy by the restoration of the endogenous
IFN system to a ‘‘naı ¨ve’’ state through a blockage of the IFN
response in nonresponders before treatment [36]. However,
modulation of ISG expression before IFN therapy may induce a
flare of HCV propagation in the liver of chronic hepatitis C
patients. Therefore, it might be interesting to examine whether an
effectiveness of cIRF7 are sustained in a state of occurring a
negative regulator for IFN signaling pathway and preactivated
IFN signaling pathway in cells replicating HCV.
VAP-A and VAP-B are suggested to be involved in the
construction of the HCV replication complex consisting of viral
proteins and host cellular lipid components, and that VAP-C
interruptstheVAP-AandVAP-Bfunctionsandnegativelyregulates
the HCV propagation and not expressed in human hepatocytes
probably involves in the determination of tissue tropism of HCV
[20]. Although further studies will be needed to elucidate the
effectiveness of the molecules in vivo experiment using drug delivery
systems including viral and non-viral vectors in more detail,
therapeutic molecules consisting of host factors involved in IFN
induction such as IRF7 and in the suppression of HCV replication
such as VAP-C fused with the IPS-1 sequences specifically cleaved
by the HCV protease might be a promising approach capable of
eliminating HCV without induction of severe cellular toxicity.
Materials and Methods
Cells and viruses
Vero and 293T cell lines were purchased from American Type
Culture Collection (Manassas, VA). Huh7 cell line was kindly
providedbyRalfBartenschlager.Huh7OK1cellline waspreviously
established from interferone-treated Huh7 cells including HCV
replicon and exhibited high susceptibility to HCVcc propagation
[38]. These cell lines were maintained in Dulbecco’s modified
Eagle’s medium (DMEM) (Sigma, St. Louis, MO) supplemented
with10%fetal calf serum (FCS). Huh-9–13 cellsharboringanHCV
subgenomic RNA replicon of genotype 1b [39] were cultured in
DMEM supplemented with 10% FCS, 1 mg/ml G418 and
nonessential amino acids. The infectious RNA of the JFH1 strain
was introduced into Huh7OK1 cells and the infectious titers were
expressed as focus-forming units (FFU) [4]. Huh7 cells harboring a
JEV subgenomic RNA replicon (Nakayama strain) were cultured in
DMEM supplemented with 10% FCS and 1 mg/ml puromycin.
Preparation of the HCV subgenomic replicon cells 4bR exhibiting
an IFN-resistant phenotype and their cured cells 4bRc were
described previously [27,28]. All cells were cultured at 37uCi na
humidified atmosphere with 5% CO2.
Plasmids and reagents
The cDNA fragments encoding IRF3 and IRF7 were amplified
by PCR from a total RNA from THP-1 cells and cloned into
Figure 5. Activation of cIRF7 in cells expressing HCV protease.
(A) Huh7OK1 cells (5610
4 cells/well) were co-transfected with plasmids
encoding either EGFP-cIRF7 or EGFP-cIRF7(C508A) and plasmids
encoding either HCVNS3/4A, HCVNS3/4A(S139A) or NS5A, harvested
at 24 h post-transfection, fixed with 4% paraformaldehyde in PBS, and
permeabilized with 0.25% saponin. HCV NS3 and NS5A were stained
with the appropriate antibodies, followed by staining with AF594-
conjugated second antibodies. (B) HCV replicon cells (5610
4 cells/well)
were transfected with plasmids encoding either EGFP-cIRF7 or EGFP-
cIRF7(C508A), and endogenous expression of HCV NS3 and an ER
marker, PDI, was detected in cells treated and stained with the
appropriate antibodies as described above. Subcellular localization of
cIRF7s, HCV proteins and PDI was determined by confocal microscopy
after staining of nuclei by DAPI. The data shown in this figure are
representative of three independent experiments.
doi:10.1371/journal.pone.0015967.g005
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carrying a deletion in the auto-inhibitory domain (from amino acid
residue 284 to 454) of IRF7 and the substitution of Ser
396 with
phosphomimetic Asp located in the carboxyl terminus of IRF3
were generated by the method of splicing by overlap extension and
cloning into pcDNA3.1myc-His and designated as IRF7m and
IRF3m, respectively. N-terminally FLAG-tagged wild-type NS3/
4A protease and its mutant substituted with Ser
139 to replaced with
Ala (S139A) were prepared as described previously [33]. The
cDNA fragment encoding a JEV protease was amplified from a
total RNA of Vero cells infected with JEV (AT31 strain) and
cloned into pcDNA3.1Flag/HA [40], The cDNA fragment
Figure 6. Suppression of HCV replication by the expression of cIRF7. (A) HCV replicon cells (3610
5 cells/well) and (B) Huh7OK1 cells (1.5610
5
cells/well) infected with HCVcc at an moi of 1 and incubated for 72 h were transfected with a plasmid encoding either empty vector (EV), cIRF7 or
cIRF7(C508A), and the expression of NS5A, cIRF7s and GAPDH (upper panels) and synthesis of viral RNA (lower panels) were determined at 72 h post-
transfection by immunoblotting and real-time PCR, respectively. (C upper left) HCV Con1 replicon cells and 4bR replicon cells exhibiting an IFN-
resistant phenotype (1.5610
5 cells/well) were treated with the CsA (5 mg/ml) or 10
4,1 0
3, and 10
2 units/ml of recombinant human IFNa and the
expressions of NS5A and GAPDH were determined by immunoblotting. The 4bR replicon cells (3610
5 cells/well) were transfected with EV or plasmid
encoding either cIRF7 or cIRF7(C508A), and the expressions of NS5A, cIRF7s and GAPDH (C upper right) and synthesis of viral RNA (C lower right) were
determined at 72 h post-transfection by immunoblotting and real-time PCR, respectively. The 4bR cells and their cured cells (4bRc) with the HCV
genome eliminated (1610
5 cells/well) were transfected with EV or plasmid encoding either cIRF7 or cIRF7(C508A) together with 100 ng of plasmid
encoding the luciferase gene under the control of the ISRE promoter, and luciferase activity was determined at 24 h post-transfection (C lower left).
The data shown in this figure are representative of three independent experiments. The error bars represent the standard deviations. Asterisks
indicate significant differences (*P,0.05, **P,0.01) versus the control cells or mock-infected cells.
doi:10.1371/journal.pone.0015967.g006
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provided by Dr. H. Akari) [41] by PCR and cloned into
pcDNA3.1Flag/HA. The chimeric IRF7 (cIRF7) composed of
the IRF7m fused with FLAG-tag and the C-terminus of human
IPS-1 (from amino acid residues 503 to 540 amino acid residues)
containing a cleavage site of HCV NS3/4A, transmembrane
domain and the ER retention signal [21] (Fig. 2A) was cloned into
pcDNA3.1-c-myc-His. A cIRF7 mutant, C508A, was generated to
be resistant to HCV NS3/4A protease by substitution of Cys
508 of
cIRF7 to Ala. The reporter constructs of IFNa6, IFNb, and ISRE
were kindly provided by Drs. T. Kawai and S. Akira. All PCR
products were confirmed by sequencing by an ABI PRISM 310
genetic analyzer (Applied Biosystems, Tokyo, Japan). The HCV
NS3/4A protease inhibitor, BILN2061 was purchased from Acme
Bioscience (Belmont, CA). Human recombinant IFNa and
cyclosporine A (CsA) were purchased from PBL Biomedical
Laboratories (New Brunswick, NJ) and Wako Pure Chemical
Industries (Osaka, Japan), respectively.
Reporter assay
Huh7 cells, HCV replicon cells, and Huh7OK1 cells infected
with HCVcc were seeded onto 12-well plates at the concentration
of 1.5610
5 cells/well and transfected with 100 ng of each of the
plasmids encoding the luciferase gene under the control of the
IFNa6, IFNb and ISRE promoter together with the various
constructs by using FuGene
TM6 (Roche Molecular Biochemicals,
Mannheim, Germany). Luciferase activity was determined by the
Dual-luciferase reporter assay system (Promega Inc., Madison, WI)
and the Renilla luciferase reporter gene was simultaneously
transfected as an internal control.
Immunoblotting
HCV replicon cells and Huh7OK1 cells infected with HCVcc
were transfected with the plasmids encoding each of the wild-type
and the dominant active mutants of IRFs and harvested at 72 h
post-transfection. Cells were washed three times with ice-cold
phosphate-buffered saline (PBS), suspended in lysis buffer
containing 20 mM Tris-HCl (pH 7.4), 135 mM NaCl, 1% Triton
X-100, 10% glycerol and protease inhibitor cocktail tablets (Roche
Molecular Biochemicals) and centrifuged at 14,0006g for 15 min
at 4uC after incubation for 30 min at 4uC. Cell lysates were
subjected to sodium dodecyl sulfate-12.5% polyacrylamide gel
electrophoresis (SDS-PAGE) after boiling in sample buffer and
transferred to polyvinylidene difluoride membranes (Millipore,
Tokyo, Japan). The membranes were blocked with PBS containing
0.05% Tween 20 and 5% skim milk at room temperature for 1 h,
incubated with mouse monoclonal anti-FLAG M2 (Sigma), anti-
hemagglutinin (HA) 16B12 (HA.11; BabCO, Richmond, CA),
anti-NS5A mouse monoclonal antibody (Austral Biologicals, San
Ramon, CA), anti-GAPDH (Santa Cruz Biotechnology, Santa
Cruz, CA), or anti-hexahistidine monoclonal antibody (Santa
Cruz) at room temperature for 1 h, and then with horseradish
peroxidase-conjugated anti-mouse IgG or anti-rabbit IgG anti-
body at room temperature for 1 h. The immune complexes were
visualized with Super Signal West Femto substrate (Pierce,
Rockford, IL) and detected by an LAS-3000 image analyzer
system (Fujifilm, Tokyo, Japan).
Quantitative reverse-transcription polymerase chain
reaction (qRT-PCR)
A total RNA was prepared from HCV replicon cells and
Huh7OK1 cells infected with HCVcc transfected with the
plasmids encoding each of the IRF constructs using an RNeasy
Figure 7. Suppression of HCV replication by the expression of
cVAP-C. (A) Schematic representation of cVAP-C, cVAP-C(C508A) and
VAP-C. Like cIRF7, cVAP-C is composed of the sequences of VAP-C,
FLAG-tag, and the C-terminus domain of IPS-1. (B) Huh7OK1 cells
(1.5610
5 cells/well) infected with HCVcc at an moi of 1 and incubated
for 72 h were transfected with EV, or plasmid encoding either cIRF7 or
cIRF7(C508A), and the expressions of NS5A, VAP-Cs and GAPDH (top
panel), synthesis of viral RNA (middle panel) and infectious titers in the
culture supernatants were determined at 72 h post-transfection by
immunoblotting, real-time PCR, and focus forming assay, respectively.
The data shown in this figure are representative of three independent
experiments. The error bars represent the standard deviations. Asterisks
indicate significant differences (*P,0.05, **P,0.01) versus the control
cells or mock-infected cells.
doi:10.1371/journal.pone.0015967.g007
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synthesized by using ReverTra Ace (TOYOBO, Osaka, Japan)
and oligo (dT)20 primer. The expression of each cDNA was
estimated by Platinum SYBR Green qPCR SuperMix UDG
(Invitrogen) according to the manufacturer’s protocol. Fluorescent
signals were analyzed by an ABI PRISM 7000 (Applied
Biosystems). The HCV and GAPDH genes were amplified using
the primer pairs of 59-GAGTGTCGTGCAGCCTCCA-39 and
59-CACTCGCAAGCACCCTATCA-39, and 59-ACCACAGTC-
CATGCCATCAC-39 and 59-TCCACCACCCTGTTGCTGTA-
39, respectively. The expression of each of mRNA was normalized
with that of GAPDH.
Subcellular localization of cIRF7 in HCV- replicating cells
Cells transfected with the plasmids were harvested at 24 h post
transfection, washed twice with PBS, fixed with PBS containing
4% paraformaldehyde, and permeabilized by incubation with PBS
containing 0.25% saponin for 10 min. Cells were incubated for
1 h at 4uC with 1mg/ml of anti-NS3 (251) mouse monoclonal
antibody (Santa Cruz), anti-NS5A mouse monoclonal antibody
(Austral Biologicals), or mouse monoclonal antibody to protein
disulfide isomerase (PDI) (Affinity Bioreagents, Golden, CO) in
PBS containing 10% FCS (PBSF), and then incubated at room
temperature for 1 h with 0.5 mg/ml of Alexa Flour 594-
conjugated anti-mouse IgG (Molecular Probes, Eugene, OR) after
three time washes with PBSF. Cell nuclei were stained with 49,6 -
diamidino-2-phenylindole (DAPI). After an extensive wash with
PBSF, the samples were examined with a Fluoview FV1000 laser
scanning confocal microscope (OLYMPUS, Tokyo, Japan).
Statistical analysis. Results were expressed as the mean 6
standard deviation. The significance of differences in the means
was determined by Student’s t test.
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